China Medical System Hldgs 

€1.53
13
+€0.06+4.08% Today

Statistics

Day High
1.53
Day Low
1.53
52W High
1.65
52W Low
0.81
Volume
-
Avg. Volume
-
Mkt Cap
3.73B
P/E Ratio
18.38
Dividend Yield
2.45%
Dividend
0.04

Upcoming

Dividends

2.45%Dividend Yield
Sep 25
€0.02
May 25
€0.01
Sep 24
€0.02
May 24
€0.01
Sep 23
€0.04
10Y Growth
2.79%
5Y Growth
-11.25%
3Y Growth
-22.86%
1Y Growth
N/A

Earnings

16MarExpected
Q4 2020
Q1 2021
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0
0.03
0.05
0.08
Expected EPS
0.0414584
Actual EPS
0.0328808

Financials

21.66%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
1.96BRevenue
425.32MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2M7C.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap2.91B
Zai Lab Limited operates in the biopharmaceutical sector within China, focusing on bringing transformative medicines, which puts it in direct competition with China Medical System Holdings in several therapeutic areas.
HUTCHMED (China) Limited
HCM
Mkt Cap2.52B
Hutchison China MediTech Limited, known as Chi-Med, is a biopharmaceutical company that develops cancer and immunological drugs, competing with China Medical System Holdings in the specialty pharma sector.
Sinopharm Group
SHTDY
Mkt Cap7.78B
Shanghai Fosun Pharmaceutical Group is a leading healthcare group in China, offering a wide range of pharmaceutical products and medical services, competing across several of the same markets as China Medical System Holdings.
Repligen
RGEN
Mkt Cap8.39B
Repligen Corporation is a bioprocessing company that, while based in the US, competes globally, including in China, in the biopharmaceutical field, indirectly competing with China Medical System Holdings through its support of biopharmaceutical manufacturing.
Perrigo Company
PRGO
Mkt Cap2.85B
Perrigo Company plc is an Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while it operates in a different segment, it competes in the broader pharmaceutical market, including areas where China Medical System Holdings is active.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc is a global healthcare company that, through its pharmaceuticals and vaccines, competes in various therapeutic areas, including those targeted by China Medical System Holdings.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a Swiss multinational pharmaceutical company that operates globally, including in China, offering products in multiple therapeutic areas that overlap with China Medical System Holdings' portfolio.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medicines, vaccines, biologic therapies, and animal health products, competing in several therapeutic areas with China Medical System Holdings.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a global pharmaceutical corporation that develops and manufactures healthcare products, including those in areas that compete with China Medical System Holdings' portfolio.

About

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Show more...
CEO
Mr. Kong Lam
Employees
6095
Country
KY
ISIN
KYG211081248
WKN
000A1JLYP

Listings

0 Comments

Share your thoughts

FAQ

What is China Medical System Hldgs stock price today?
The current price of 2M7C.F is €1.53 EUR — it has increased by +4.08% in the past 24 hours. Watch China Medical System Hldgs stock price performance more closely on the chart.
What is China Medical System Hldgs stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange China Medical System Hldgs stocks are traded under the ticker 2M7C.F.
Is China Medical System Hldgs stock price growing?
2M7C.F stock has risen by +10.07% compared to the previous week, the month change is a +0.66% rise, over the last year China Medical System Hldgs has showed a +61.9% increase.
What is China Medical System Hldgs market cap?
Today China Medical System Hldgs has the market capitalization of 3.73B
When is the next China Medical System Hldgs earnings date?
China Medical System Hldgs is going to release the next earnings report on August 13, 2026.
What were China Medical System Hldgs earnings last quarter?
2M7C.F earnings for the last quarter are 0.03 EUR per share, whereas the estimation was 0.04 EUR resulting in a -20.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is China Medical System Hldgs revenue for the last year?
China Medical System Hldgs revenue for the last year amounts to 1.96B EUR.
What is China Medical System Hldgs net income for the last year?
2M7C.F net income for the last year is 425.32M EUR.
Does China Medical System Hldgs pay dividends?
Yes, 2M7C.F dividends are paid semi-annual. The last dividend per share was 0.02 EUR. As of today, Dividend Yield (FWD)% is 2.45%.
How many employees does China Medical System Hldgs have?
As of April 02, 2026, the company has 6,095 employees.
In which sector is China Medical System Hldgs located?
China Medical System Hldgs operates in the Health Care sector.
When did China Medical System Hldgs complete a stock split?
The last stock split for China Medical System Hldgs was on April 27, 2012 with a ratio of 3:2.
Where is China Medical System Hldgs headquartered?
China Medical System Hldgs is headquartered in North Point, KY.